Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

Clinical Therapeutics

Volumn 22, Issue SUPPL. B, 2000, Pages

  MacDonald, Allan S ^a   Scarola, Joseph ^b   Burke, James T ^c   Zimmerman, James J ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b WYETH AYERST RESEARCH   (United States)

^c Searle European Clinical R and D   (France)

Author keywords

Drug monitoring; Pharmacodynamics; Pharmacokinetics; Rapamycin; Sirolimus

Indexed keywords

ACICLOVIR; CYCLOSPORIN; DIGOXIN; DILTIAZEM; ESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTREL; GLIBENCLAMIDE; KETOCONAZOLE; NIFEDIPINE; RAPAMYCIN; RIFAMPICIN;

ARTICLE; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PHARMACODYNAMICS;

EID: 0034065402     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)89027-X     Document Type: Article

References (46)

1. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot. 1975;28:721-726.
2. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J Antibiot. 1975;28:727-732.
3. Morris RE. Rapamycins: Antifungal, anti-tumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev. 1992; 6:39-87.
4. Kahan BD. Sirolimus: A new agent for clinical renal transplantation. Transplant Proc. 1997;29:48-50.
5. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996;14:483-510.
6. Sehgal SN, Camardo JS, Scarola JA, Maida BT. Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens. 1995;4:482-487.
7. Liu J, Albers MW, Wandless TJ, et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry. 1992;31:3896-3901.
8. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of protein target of FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1994;270:815-822.
9. Terada N, Lucas JJ, Szepesi A, et al. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cell cycle. J Cell Physiol. 1993;154:7-15.
10. Sehgal SN. Therapeutic index and pharmacokinetic/pharmacodynamic study in orthotopic renal transplanted pigs after P.O. administration of rapamycin. Wyeth-Ayerst GTR-25118, 1994.
11. Kahan BD, Julian B, Pescovitz MD, et al, for the Sirolimus Study Group. Sirolimus (rapamycin) phase II study: Low incidence of acute rejection in recipients of mismatched primary renal allografts. Transplantation. 1999;68:1526-1532.
12. Groth CG, Backman L, Morales J-L, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation. 1999;67:1036-1042.
13. Kreis H, Cisterne JM, Land L, et al. Sirolimus in association with mycophenolate mofetil in renal allograft recipients. Transplantation. In press.
14. MacDonald A. A randomized trial of sirolimus, cyclosporine and prednisone vs cyclosporine and prednisone alone in recipients of mismatched first kidney grafts: Results at one year. Transplantation. 1999;67(Suppl 9):S546. Abstract 15.
15. Kahan B. Pivotal phase III multicenter, randomized, blinded trial of sirolimus versus azathioprine in combination with cyclosporine and prednisone in primary renal transplants. Transplantation. 1999;67 (Suppl 9). Abstract 68.
16. Brattstrom C, Sawe J, Lonnebo A, et al. Safety and pharmacokinetics of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit. In press.
17. Tejani A, Alexander S, Kohaut E, et al. Safety and pharmacokinetic profile of ascending single doses of oral liquid sirolimus (rapamycin) in pediatric patients with stable chronic renal failure. Transplantation. 1999;67(Suppl):S125. Abstract.
18. Kumi KA. 21083A Rapamune (sirolimus) oral solution. Clinical pharmacology and biopharmaceutics review(s). Available at: http://www.fda.gOv/cder/foi/nda/99/2108 3a_rapamune_clinphrmr.pdf.
19. Johnson EM, Zimmerman J, Duderstadt K, et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc. 1996;28(Suppl 2):S987. Abstract.
20. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 1997;37:405-415.
21. Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 1997;61:416-428.
22. Brattstrom C, Sawe J, Tyden G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit. 1997;19:397-406.
23. Zheng J, Sambol NC, Zimmerman J, Zaidi A. Population pharmacokinetics (PK) of sirolimus. Clin Pharmacol Ther. 1996; 59(Suppl 2):S150. Abstract.
24. Physicians' Desk Reference®. 54th ed. Montvale, NJ: Medical Economics Company; 2000.
25. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998; 285:1104-1112.
26. Sattler M, Guengerich FP, Yun C-H, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
27. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model rats: Comparison with rapamycin. Pharm Res. 1998;15: 1666-1672.
28. Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol. 1999;39:1155-1161.
29. Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation. 1993;56:1202-1206.
30. Leung LY, Lim H-K, Hicks D, et al. Sirolimus (rapamycin): Metabolite characterization in rat and human liver microsomal incubations and trough whole blood of renal transplant patients treated with sirolimus, cyclosporine, and prednisone. ISSX Proc. 1996;10:366. Abstract.
31. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992;20: 186-191.
32. 14C-radiolabeled drug (nominal 40 mg). Wyeth-Ayerst GTR-29528, 1997.
33. Jusko WJ, Ferron GM, Mis SM, et al. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J Clin Pharmacol. 1996;36:1100-1106.
34. Backman L, Brattstrom C, Claesson K, et al. The effect of sulfamethoxazoletrimethoprim on the pharmacokinetics of sirolimus in renal transplant recipients. Paper presented at: Ninth Congress of the European Society of Transplantation; June 1999; Oslo, Norway. Abstract.
35. Kaplan B, Meier-Kriesche H-U, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther. 1998;63:48-53.
36. Kahan BD, Napoli KL. Role of therapeutic drug monitoring of rapamycin. Transplant Proc. 1998;30:2189-2192.
37. Fawl RL, Goldberg-Alberts MA, Zimmerman JJ. A double-blind, comparative study of the effect of two dose levels of sirolimus versus azathioprine, administered concomitantly with standard immunosuppressive therapy in renal allograft recipients: 6-month report (Protocol 0468E1-301-US), GMR-32348, 1998.
38. Miller M, Wickersham P, Goldberg-Alberts R, et al. A placebo-controlled, double-blind study of the effect of two dose levels of sirolimus plus standard immunosuppressive therapy in renal allograft recipients: 6-month report. Wyeth-Ayerst GMR-33147, 1998.
39. Jones K, Saadat-Lajevardi S, Lee T, et al. An immunoassay for the measurement of sirolimus. Clin Ther. 2000;22(Suppl B): B49-B61.
40. SAS/STAT® User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc.; 1989.
41. Chiang ST. Update summary report of exploratory pharmacodynamic analysis of sirolimus based on pooled data of protocols 301-US and 302-GL. Wyeth-Ayerst GTR-37247, 1999.
42. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62:248-260.
43. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation. 1995;59:1683-1689.
44. Kahan BD, Jaffe JS. Triglyceride (TG) elevations in renal transplant recipients treated with sirolimus (rapamycin, RAPA) added to a cyclosporine (CsA)/prednisone (pred) regimen. Paper presented at: Annual Meeting of the American Society of Transplantation and the American Society of Transplant Surgeons; May 15-21, 1999; Chicago, Ill. Abstract 172.
45. Neylan JF, Wickersham P, Jaffe J. Effect of race on efficacy and safety of sirolimus vs AZA + standard immunotherapy in renal transplantation. Paper presented at: Annual Meeting of the American Society of Transplantation and the American Society of Transplant Surgeons; May 15-21, 1999; Chicago, Ill. Abstract 924.
46. Kaplan B, Meier-Kriesche H-U, Napoli K, Kahan BD. A limited sampling strategy for estimating sirolimus area-under-the-concentration curve. Clin Chem. 1997;43:539-540.